A PROFESSOR at Sheffield University has presented a report claiming that one in five deaths following a heart attack could be prevented if a new drug was used over standard treatment.
Robert Storey, professor of cardiology at the department of cardiovascular science, has presented his findings into the use of ticagrelor over clopidogrel at the British Cardiovascular Society’s annual scientific conference, this year held in Manchester.
Prof Storey has led UK investigations into ticagrelor and was a member of the international committee that conducted the PLATO study, a trial of over 18 thousand patients in over 40 countries around the world.
The results of the study were first presented at the European Society of Cardiology congress in 2009.
It showed that ticagrelor was more effective for heart attack patients than clopidogrel in reducing death and recurrent heart attack.
Now new analysis of the PLATO study – presented this year at the American College of Cardiology – showed that ticagrelor is just as effective at reducing deaths in patients over the age of 75 as in younger patients.
Prof Storey said: “Our new findings really highlight the universal applicability of the treatment.”